Research programme: cancer immunotherapies - OncoQR/TYG Oncology

Drug Profile

Research programme: cancer immunotherapies - OncoQR/TYG Oncology

Alternative Names: OQR 100; OQR 200; TYG 100

Latest Information Update: 18 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoQR
  • Class Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Gastric cancer; Oesophageal cancer; Pancreatic cancer

Highest Development Phases

  • Preclinical Breast cancer; Gastric cancer; Pancreatic cancer

Most Recent Events

  • 11 Mar 2016 TYG 100 is available for licensing as of 11 Mar 2016. http://www.tyg-oncology.com/
  • 11 Mar 2016 Immunogenicity, pharmacodynamics and safety data from a preclinical study in Pancreatic cancer released by TYG Oncology
  • 11 Mar 2016 TYG 100 and S-TIR™ technology platform licensed to TYG Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top